Vertex Pharmaceuticals(VRTX)
Focus: Vertex is a $9.9B revenue public biotech leader focused on CF, pain, sickle cell, and rare diseases with a diversified pipeline across small molecules and cell therapy. The company commands 92% revenue concentration from KALYDECO, its flagship CF drug, generating $25M in Part D spending alone.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
10,400
Open Jobs
238-34 this month
Contracting — net -34 jobs in 30d
101 added, 135 removed. Active reduction in progress.
Should You Work at Vertex Pharmaceuticals?
AI assessmentVertex is a high-growth specialty pharma with financial strength and hiring momentum, but revenue concentration and near-term patent cliffs require pipeline success to justify long-term career commitment.
Why Work Here
- Strong revenue trajectory ($9.9B FY2025, up 11% YoY) with exceptional profitability ($3.6B net income) and $10.5B cash position provides stability and R&D investment
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
2 in 5yr
INCIVEK
Hiring
Stable
Revenue
$9.9B
FY2025
Key Products
$25M Part DStable
Peak7.2yr
Help build intelligence for Vertex Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.